Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Matthew R. Sydes"'
Autor:
Hussein Ibrahim, Xiaoxuan Liu, Samantha Cruz Rivera, David Moher, An-Wen Chan, Matthew R. Sydes, Melanie J. Calvert, Alastair K. Denniston
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-5 (2021)
Abstract Background The application of artificial intelligence (AI) in healthcare is an area of immense interest. The high profile of ‘AI in health’ means that there are unusually strong drivers to accelerate the introduction and implementation o
Externí odkaz:
https://doaj.org/article/5768b33cd0664f9e8695072e1ad62d0e
Autor:
Ian R White, Babak Choodari-Oskooei, Matthew R Sydes, Brennan C Kahan, Leanne McCabe, Anna Turkova, Hanif Esmail, Diana M Gibb, Deborah Ford
Publikováno v:
Clinical trials (London, England). 19(4)
Background Factorial designs and multi-arm multi-stage (MAMS) platform designs have many advantages, but the practical advantages and disadvantages of combining the two designs have not been explored. Methods We propose practical methods for a combin
Publikováno v:
Clinical trials (London, England). 19(2)
Autor:
Sharon B. Love, Fay Cafferty, Claire Snowdon, Karen Carty, Joshua Savage, Philip Pallmann, Lucy McParland, Louise Brown, Lindsey Masters, Francesca Schiavone, Dominic Hague, Stephen Townsend, Claire Amos, Annabelle South, Kate Sturgeon, Ruth Langley, Timothy Maughan, Nicholas James, Emma Hall, Sarah Kernaghan, Judith Bliss, Nick Turner, Andrew Tutt, Christina Yap, Charlotte Firth, Anthony Kong, Hisham Mehanna, Colin Watts, Robert Hills, Ian Thomas, Mhairi Copland, Sue Bell, David Sebag-Montefiore, Robert Jones, Mahesh K. B. Parmar, Matthew R. Sydes
Publikováno v:
Trials
Background Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640f4347bd17b86b6a18fa1d45321a9f
https://eprints.gla.ac.uk/279671/1/279671.pdf
https://eprints.gla.ac.uk/279671/1/279671.pdf
Publikováno v:
Clinical Trials (London, England)
CLINICAL TRIALS
Lane, J A, Gamble, C, Cragg, W J, Tembo, D & Sydes, M R 2020, ' A third trial oversight committee : Functions, benefits and issues ', Clinical Trials, vol. 17, no. 1, pp. 106-112 . https://doi.org/10.1177/1740774519881619
CLINICAL TRIALS
Lane, J A, Gamble, C, Cragg, W J, Tembo, D & Sydes, M R 2020, ' A third trial oversight committee : Functions, benefits and issues ', Clinical Trials, vol. 17, no. 1, pp. 106-112 . https://doi.org/10.1177/1740774519881619
Background/aims: Clinical trial oversight is central to the safety of participants and production of robust data. The United Kingdom Medical Research Council originally set out an oversight structure comprising three committees in 1998. The first com
Autor:
Anna Hockaday, Rebecca Maier, Munyaradzi Dimairo, Philip Pallmann, Rachel Lowe, Jamie Hall, Jessica Welburn, Mark Pilling, Nina Wilson, Sarah Bowden, Sofia S. Villar, James Wason, Matthew R. Sydes, Caroline Murphy, Claire Snowdon, Laura Flight, Thomas Jaki, Christopher J. Weir, Julia Brown, Christina Yap, Helen C. Hancock, Katie Biggs
Publikováno v:
BMC Medicine
Wilson, N, Biggs, K, Bowden, S, Brown, J, Dimairo, M, Flight, L, Hall, J, Hockaday, A, Jaki, T, Lowe, R, Murphy, C, Pallmann, P, Pilling, M, Snowdon, C, Sydes, M R, Villar, S S, Weir, C J, Welburn, J, Yap, C, Maier, R, Hancock, H & Wason, J 2021, ' Costs and Staffing Resource Requirements for Adaptive Clinical Trials : Quantitative and qualitative results from the Costing Adaptive Trials Project ', BMC Medicine, vol. 19, 251 . https://doi.org/10.1186/s12916-021-02124-z
BMC Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Wilson, N, Biggs, K, Bowden, S, Brown, J, Dimairo, M, Flight, L, Hall, J, Hockaday, A, Jaki, T, Lowe, R, Murphy, C, Pallmann, P, Pilling, M, Snowdon, C, Sydes, M R, Villar, S S, Weir, C J, Welburn, J, Yap, C, Maier, R, Hancock, H & Wason, J 2021, ' Costs and Staffing Resource Requirements for Adaptive Clinical Trials : Quantitative and qualitative results from the Costing Adaptive Trials Project ', BMC Medicine, vol. 19, 251 . https://doi.org/10.1186/s12916-021-02124-z
BMC Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Background Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials. An important barrier to further increased use is a lack of understanding about which additional resources are required to conduct a hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda3ef3551003264c2a72f967a20005c
Autor:
Tim Maughan, Joshua Hordern, Louise Brown, Richard Kaplan, Liz Morrell, Parmar Mkb., Matthew R. Sydes, Claire Amos
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-6 (2019)
Trials
Trials
Background Trials have become bigger and more complicated due to the complexity introduced by biomarker stratification, and the advent of multi-arm multi-stage trials, and umbrella and basket platform designs. The trials unit at University College Lo
Autor:
Nurulamin M Noor, Sharon B Love, Talia Isaacs, Richard Kaplan, Mahesh K B Parmar, Matthew R Sydes
Publikováno v:
BMJ Open. 12:e055615
BackgroundFor medical conditions with numerous interventions worthy of investigation, there are many advantages of a multi-arm multi-stage (MAMS) platform trial approach. However, there is currently limited knowledge on uptake of the MAMS design, esp
Autor:
Angela M. Crook, Claire L Vale, Nurulamin M Noor, Sarah Pett, Hanif Esmail, Matthew R. Sydes, Mahesh K. B. Parmar
Publikováno v:
F1000Research
Global health pandemics, such as coronavirus disease 2019 (COVID-19), require efficient and well-conducted trials to determine effective interventions, such as treatments and vaccinations. Early work focused on rapid sequencing of severe acute respir
Autor:
Deepika Reddy, John Staffurth, Chris Dobbs, Emily Day, Manit Arya, Hashim U. Ahmed, Stuart McCracken, Mark Emberton, Matthew R. Sydes, A T Prevost, Mathias Winkler, Tim Dudderidge, Francesca Fiorentino, Taimur T. Shah
Introduction Focal therapy (FT) targets individual areas of cancer within the prostate, providing oncological control with minimal side-effects. Early evidence demonstrates encouraging short-medium-term outcomes. With no randomized controlled trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca44ec45aca8908075410a9be26ace5e